CD30 expression is not a predictive marker of clinical response to brentuximab vedotin treatment, therefore, development of a biomarker that can identify patients who respond to this agent is ...

Genome Therapeutics Ltd. has synthesized compounds and their immunoconjugates comprising an antibody covalently linked to a cytotoxic drug through a linker reported to be useful for the treatment of ...

Genome Therapeutics Ltd. has disclosed compounds and their immunoconjugates comprising an antibody covalently linked to a cytotoxic drug through a linker reported to be useful for the treatment of ...

Researchers at the University of California San Diego School of Medicine have identified a promising new therapy for triple-negative breast cancer (TNBC), which is among the most aggressive and ...